PBLA

0.000150.00%
MT

Michael T. Cullen

Chairman

Dr. Michael T. Cullen, Jr., M.D., M.B.A., has been Chairman of Panbela Therapeutics Inc. (formerly known as Sun BioPharma, Inc.) since May 25, 2021, had been its Executive Chairman from 2015 to May 25, 2021 and has been its Director since September 4, 2015. Dr. Cullen served as Chief Executive Officer and President of Panbela Therapeutics Inc. (formerly known as Sun BioPharma, Inc.) since October 31, 2018 until July 15, 2020. He Co-founded Panbela Therapeutics Inc. (formerly known as Sun BioPharma, Inc.) in November 2011 and served as its Chief Medical Officer from November 2011 to January 2015 and President from November 2011 to April 2, 2016. Dr. Cullen served as Vice President and Medical Director of SunPharm Corporation since September 1998. Prior to that, Dr. Cullen served as Vice President of Clinical consulting of IBAH Clinical Consulting Services from 1997 to 1998, where he provided consulting services on business strategy, creating development plans, regulatory matters & designing clinical trials for several development stage companies in the pharmaceutical industry and from 1995 to 1997 Vice President and Medical Director of IBAH U.S. Business Development. He Co-founded Cimarron Medical, Inc. and served as its President and Chairman. Dr. Cullen worked at G.D. Searle, SunPharm Corporation as Chief Medical Officer. Dr. Cullen was a Co-Founder of IDD Medical, Inc. and served as its Chief Executive Officer from 1994 to 1995. He served as Assistant and Associate Director for Clinical Research of 3M Pharmaceuticals from 1988 to 1994. Dr. Cullen practiced from 1977 to 1988 at Owatonna Clinic, Owatonna, MN, where he served as President. Dr. Cullen joined MGI PHARMA as Vice President, Clinical Affairs and Chief Medical Officer since September 7, 2000 until 2008, where he developed several oncology drugs. Dr. Cullen has medical and pharmaceutical industry experience. He served as Medical Director for global medical operations and marketing of Searle/Pharmacia Corporation. Previously, he was a Consultant in Internal medicine in Owatonna, Minnesota from 1977 to 1988 and served with the National Center for Disease Control from 1972 to 1974. He is certified by the American Board of Internal Medicine and practiced for more than a decade at the Owatonna Clinic, P.A. in Owatonna, Minnesota where he served as President. He is expertise in working with development-stage companies in planning, designing, and advancing drug candidates from preclinical through clinical development. He is an experienced drug development specialist. Dr. Cullen provided due diligence consulting to the pharmaceutical industry from 2009 to 2011, after in transition consulting to Eisai Pharmaceuticals. Dr. Cullen joined 3M Pharmaceuticals in 1988 and contributed to the development of cardiovascular, pulmonary, rheumatology and immune-response modification drugs. Over the course of his career Dr. Cullen has been instrumental in obtaining the approval of ten drugs, including three since 2004: Aloxi®, Dacogen® and Lusedra®. Dr. Cullen received his BS and M.D. degrees from the University of Minnesota and his MBA from the University of St. Thomas, in St. Paul, Minnesota in 1991 and completed his residency and Board certification in Internal Medicine through University of North Carolina in Chapel Hill and Wilmington, NC.

Positions